<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807377</url>
  </required_header>
  <id_info>
    <org_study_id>B1731021</org_study_id>
    <nct_id>NCT01807377</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects</brief_title>
  <official_title>A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability and pharmacokinetics of multiple
      oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight
      and obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma PF-05175157 Concentration (Cmax)</measure>
    <time_frame>0 - 10 hrs postdose</time_frame>
    <description>Single Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval for PF-05175157 (AUCtau)</measure>
    <time_frame>0 - 10 hrs postdose</time_frame>
    <description>Single Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)</measure>
    <time_frame>0 - 10 hrs postdose</time_frame>
    <description>Single Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma PF-05175157 Concentration (Cmax)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
    <description>Steady State</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-05175157</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
    <description>Steady State</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma PF-05175157 Concentration (Tmax)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
    <description>Steady State</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance of PF-05175157 (CL/F)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio of PF-05175157 (Rac)</measure>
    <time_frame>0 - 10 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life of PF-05175157 (t1/2)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of PF-05175157 (Vz/F)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Recovery for PF-05175157 (AE24)</measure>
    <time_frame>0 - 24 hours postdose</time_frame>
    <description>Amount of PF-05175157 recovered in urine over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance for PF-05175157 (CLr)</measure>
    <time_frame>0 - 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration for midazolam [AUC (0-t)]</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time for midazolam [AUC (0 - inf)]</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration for midazolam (Cmax)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma midazolam Concentration (Tmax)</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life of midazolam (t1/2)</measure>
    <time_frame>0 - 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting triglycerides</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>PF-05175157, Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>200 mg tablet administered twice per day for 14 days</description>
    <arm_group_label>PF-05175157, Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2mg administered as single doses on Days 0 and 11</description>
    <arm_group_label>PF-05175157, Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered twice per day for 14 days</description>
    <arm_group_label>Placebo, Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2mg administered as single doses on Days 0 and 11</description>
    <arm_group_label>Placebo, Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible for enrollment
        into the study:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests).

          -  Women must be of non childbearing potential.

          -  Body Mass Index (BMI) of 25 to 35 kg/m2 inclusive; and a total body weight &gt;50 kg (110
             lbs).

          -  An informed consent document signed and dated by the subject.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Evidence or history of any chronic ongoing or current pulmonary disease.

          -  History of smoking in the past 5 years and a history of smoking more than 10 pack
             years, or history or evidence of habitual use of other (non smoked) tobacco or
             nicotine containing products. Active ocular disease including infection, glaucoma,
             seasonal allergies, dry eye symptoms or retinal/optic nerve disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731021&amp;StudyName=Multiple%20Dose%20Safety%20Tolerability%2C%20Pharmacokinetics%20And%20Midazolam%20Interaction%20In%20Healthy%20Overweight%20And%20Obese%20Subjects%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

